NCT00254865View on ClinicalTrials.gov

A Comparative Pharmacokinetic Study of ORTHO EVRA (a Transdermal Contraceptive Patch) and CILEST (an Oral Contraceptive) in Healthy Female Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

August 31, 2002

Study Completion Date

March 31, 2003

Conditions
ContraceptionFemale Contraception
Interventions
DRUG

EVRA® transdermal contraceptive patch containing 6 mg of norelgestromin and 0.75 mg of ethinyl estradiol (versus CILEST® tablets).

All Listed Sponsors
lead

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

INDUSTRY

NCT00254865 - A Comparative Pharmacokinetic Study of ORTHO EVRA (a Transdermal Contraceptive Patch) and CILEST (an Oral Contraceptive) in Healthy Female Volunteers | Biotech Hunter | Biotech Hunter